Trial intelligence / Profile preview

Mass balance and metabolite profile of lefamulin in healthy males

NCT03131141Phase 1Completed

Sponsor
Nabriva Therapeutics plc
Start
Jan 2017
Primary completion
Oct 2017
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, open-label trial of lefamulin in bacterial infection (2 cohorts), sponsored by Nabriva Therapeutics plc. Primary endpoints: Amount of radioactivity eliminated in urine, Amount of radioactivity eliminated in feces and 1 more. Started Jan 2017; status: completed.

02

Drugs

lefamulin
03

Conditions

bacterial infection

Beyond the preview

Go deeper on NCT03131141.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03131141.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call